Top 3 Health Care Stocks That May Explode This Month

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.

Here’s the latest list of major oversold players in this sector, having an RSI near or below 30.

Progyny Inc PGNY

On Sept. 19, the company said a client elected to exercise an option to terminate its services agreement with the company. The company’s stock fell around 32% over the past five days and has a 52-week low of $13.93.
RSI Value: 26.50
PGNY Price Action: Shares of Progyny rose 1% to close at $16.62 on Friday.
Benzinga Pro’s real-time newsfeed alerted to latest PGNY news.

Indivior PLC INDV

On Sept. 4, Indivior issued an update on Aelis Farma’s Phase 2B study with AEF0117 in participants with cannabis use disorder. It has a 52-week low of $9.14.
RSI Value: 25.92
RELI Price Action: Shares of Indivior fell 2.1% to close at $9.48 on Friday.
Benzinga Pro’s charting tool helped identify the trend in INDV stock.

Moderna Inc MRNA

On Sept. 17, Moderna announced that Health Canada approved its vaccine, SPIKEVAX, which aids in preventing COVID-19 in people six months of age or older.The vaccine targets the KP.2 variant of COVID-19. The company plans to begin delivery of the vaccine to the Public Health Agency of Canada shortly. “With the recent increase in COVID-19-infections, staying up to date with your COVID-19 vaccination remains one of the best ways to help protect yourself from severe illness,” said Dr. Shehzad Iqbal, country medical director, Moderna Canada. The company’s shares fell around 20% over the past month and has a 52-week low of $62.55.
RSI Value: 28.17
MRNA Price Action: Shares of Moderna fell 3.4% to close at $65.69 on Friday.
Benzinga Pro’s signals feature notified of a potential breakout in MRNA shares.